These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1038 related items for PubMed ID: 12592125

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H.
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [Abstract] [Full Text] [Related]

  • 3. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V, Hopper OW, Martin WH, Kikkawa R, Delbeke D.
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [Abstract] [Full Text] [Related]

  • 4. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB.
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [Abstract] [Full Text] [Related]

  • 5. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
    Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, Wikler D, Gelin M.
    J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
    [Abstract] [Full Text] [Related]

  • 6. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors.
    Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A.
    Ann Nucl Med; 2013 Jan; 27(1):58-64. PubMed ID: 23054830
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
    Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A.
    Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
    [Abstract] [Full Text] [Related]

  • 9. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
    Wudel LJ, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, Pinson CW, Chapman WC.
    Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [Abstract] [Full Text] [Related]

  • 13. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT].
    Zhao M, Wu PH, Zeng YX, Zhang FJ, Huang JH, Fan WJ, Gu YK, Zhang L, Tan ZB, Lin YE.
    Ai Zheng; 2005 Sep; 24(9):1118-23. PubMed ID: 16159437
    [Abstract] [Full Text] [Related]

  • 14. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ.
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [Abstract] [Full Text] [Related]

  • 15. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases.
    Dierckx R, Maes A, Peeters M, Van De Wiele C.
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):336-42. PubMed ID: 19521313
    [Abstract] [Full Text] [Related]

  • 16. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P, Stergar H, Forsting M, Bockisch A, Antoch G.
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H, Henderson RW, Conti PS.
    J Comput Assist Tomogr; 2007 Jul; 31(2):223-8. PubMed ID: 17414758
    [Abstract] [Full Text] [Related]

  • 20. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
    Okuma T, Okamura T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, Koyama K, Inoue K, Nakamura K, Inoue Y.
    Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.